OncoMatch/Clinical Trials/NCT02508038
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Is NCT02508038 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Zoledronate for acute myeloid leukemia.
Treatment: Zoledronate — This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Rhabdomyosarcoma
Sarcoma
Glioblastoma
Osteosarcoma
Neuroblastoma
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant — auto-HSCT ineligible or failed
Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant
Must have received: hematopoietic stem cell transplant — auto-HSCT ineligible or failed
Patients with solid tumor must have failed or have been ineligible to receive auto-HSCT or if auto-HSCT would not offer > 20% chance of cure
Lab requirements
Kidney function
Glomerular Filtration Rate (GFR) ≥ 60 ml/min/1.73m2
Liver function
Total bilirubin < 3 mg/dL; ALT (alanine aminotransferase, SCPT) ≤ 5 x Upper Limit of Normal (ULN) for age
Cardiac function
Ejection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram
Total bilirubin < 3 mg/dL; ALT (alanine aminotransferase, SCPT) ≤ 5 x Upper Limit of Normal (ULN) for age; Glomerular Filtration Rate (GFR) ≥ 60 ml/min/1.73m2; Ejection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02508038 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received hematopoietic stem cell transplant and hematopoietic stem cell transplant.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify